XNASPAVM
Market cap7mUSD
Dec 24, Last price
0.66USD
1D
1.72%
1Q
-42.95%
Jan 2017
-99.37%
IPO
-99.66%
Name
PAVmed Inc
Chart & Performance
P/E
—
P/S
2.96
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-20.15%
Rev. gr., 5y
%
Revenues
2m
+550.40%
Net income
-64m
L-36.64%
CFO
-52m
L-26.69%
Earnings
Mar 24, 2025
Profile
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | 2,452 550.40% | 377 -24.60% | 500 | |||||||
Cost of revenue | 69,226 | 89,520 | 54,893 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (66,774) | (89,143) | (54,393) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (1,944) | (5,779) | ||||||||
Tax Rate | ||||||||||
NOPAT | (66,774) | (87,199) | (48,614) | |||||||
Net income | (64,175) -36.64% | (101,294) 101.19% | (50,347) 46.66% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 1,817 | 1,520 | 555,279 | |||||||
BB yield | -6.10% | -3.56% | -291.20% | |||||||
| Debt | ||||||||||
Debt current | 45,765 | 34,791 | ||||||||
Long-term debt | 7,485 | 4,833 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 4,259,000 | |||||||||
Net debt | 33,611 | (120) | (77,258) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (52,036) | (70,985) | (40,591) | |||||||
CAPEX | (242) | (1,540) | (1,469) | |||||||
Cash from investing activities | 758 | (4,740) | (3,716) | |||||||
Cash from financing activities | 31,173 | 38,211 | 104,309 | |||||||
FCF | (67,336) | (91,102) | (50,117) | |||||||
| Balance | ||||||||||
Cash | 19,639 | 39,744 | 77,258 | |||||||
Long term investments | ||||||||||
Excess cash | 19,516 | 39,725 | 77,233 | |||||||
Stockholders' equity | (261,618) | (204,764) | (118,653) | |||||||
Invested Capital | 286,325 | 252,335 | 198,071 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 7,232 | 5,938 | 5,168 | |||||||
Price | 4.12 -42.78% | 7.20 -80.49% | 36.90 16.04% | |||||||
Market cap | 29,794 -30.32% | 42,757 -77.58% | 190,689 89.63% | |||||||
EV | 96,211 | 65,947 | 133,602 | |||||||
EBITDA | (63,842) | (86,686) | (54,167) | |||||||
EV/EBITDA | ||||||||||
Interest | 589 | 1,272 | ||||||||
Interest/NOPBT | ||||||||||